<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584736</url>
  </required_header>
  <id_info>
    <org_study_id>JWP-PTZ-301</org_study_id>
    <nct_id>NCT04584736</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia</brief_title>
  <official_title>To Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe&#xD;
      Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Randomized, Double-blinded, Active-controlled, Factorial Design Phase 3&#xD;
      Clinical Trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">October 12, 2020</completion_date>
  <primary_completion_date type="Actual">July 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% change in LDL-C level from baseline at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>change in LDL-C level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C level from baseline at Week 4 and Week 8</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <description>change in LDL-C level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Livalo 2mg, Ezetrol 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 2mg, Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Livalo 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin 2mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Livalo 4mg, Ezetrol 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 4mg, Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Livalo 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin 4mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Livalo, Ezetrol</intervention_name>
    <description>Pitavastatin+Ezetimibe Pitavastatin</description>
    <arm_group_label>Livalo 2mg</arm_group_label>
    <arm_group_label>Livalo 2mg, Ezetrol 10mg</arm_group_label>
    <arm_group_label>Livalo 4mg</arm_group_label>
    <arm_group_label>Livalo 4mg, Ezetrol 10mg</arm_group_label>
    <other_name>Pitavastatin, Ezetimibe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary hypercholesterolemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject not meet the specified LDL-C level&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>dongryeong lee, Manager</last_name>
    <role>Study Chair</role>
    <affiliation>+82-2-840-6982</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

